Your browser doesn't support javascript.
loading
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby, Mark R; DiMeglio, Linda A; Rendell, Marc S; Felner, Eric I; Dostou, Jean M; Gitelman, Stephen E; Patel, Chetanbabu M; Griffin, Kurt J; Tsalikian, Eva; Gottlieb, Peter A; Greenbaum, Carla J; Sherry, Nicole A; Moore, Wayne V; Monzavi, Roshanak; Willi, Steven M; Raskin, Philip; Moran, Antoinette; Russell, William E; Pinckney, Ashley; Keyes-Elstein, Lynette; Howell, Michael; Aggarwal, Sudeepta; Lim, Noha; Phippard, Deborah; Nepom, Gerald T; McNamara, James; Ehlers, Mario R.
Afiliação
  • Rigby MR; Indiana University and Riley Hospital for Children at Indiana University Health, Indianapolis, Indianapolis, IN, USA. Electronic address: mrigby@iu.edu.
  • DiMeglio LA; Indiana University and Riley Hospital for Children at Indiana University Health, Indianapolis, Indianapolis, IN, USA.
  • Rendell MS; Creighton Diabetes Center, Omaha, NE, USA.
  • Felner EI; Emory University, Atlanta, GA, USA.
  • Dostou JM; University of North Carolina, Durham, NC, USA.
  • Gitelman SE; University of California San Francisco, San Francisco, CA, USA.
  • Patel CM; University of Arizona, Tucson, AZ, USA.
  • Griffin KJ; University of Arizona, Tucson, AZ, USA.
  • Tsalikian E; University of Iowa, Iowa City, Iowa, USA.
  • Gottlieb PA; Barbara Davis Center, University of Colorado, Aurora, CO, USA.
  • Greenbaum CJ; Benaroya Research Institute, Seattle, WA, USA.
  • Sherry NA; Massachusetts General Hospital, Boston, MA, USA.
  • Moore WV; Children's Mercy Hospital, Kansas City, MO, USA.
  • Monzavi R; Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Willi SM; Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Raskin P; The University of Texas, Southwestern Medical Center, Dallas, TX, USA.
  • Moran A; University of Minnesota, Minneapolis, MN, USA.
  • Russell WE; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Pinckney A; Rho Federal Systems Division, Chapel Hill, NC, USA.
  • Keyes-Elstein L; Rho Federal Systems Division, Chapel Hill, NC, USA.
  • Howell M; Immune Tolerance Network, Bethesda, MD, USA.
  • Aggarwal S; Immune Tolerance Network, Bethesda, MD, USA.
  • Lim N; Immune Tolerance Network, Bethesda, MD, USA.
  • Phippard D; Immune Tolerance Network, Bethesda, MD, USA.
  • Nepom GT; Benaroya Research Institute, Seattle, WA, USA.
  • McNamara J; National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA.
  • Ehlers MR; Immune Tolerance Network, San Francisco, CA, USA.
Lancet Diabetes Endocrinol ; 1(4): 284-94, 2013 Dec.
Article em En | MEDLINE | ID: mdl-24622414
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Linfócitos T / Sistemas de Liberação de Medicamentos / Diabetes Mellitus Tipo 1 / Memória Imunológica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2013 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Linfócitos T / Sistemas de Liberação de Medicamentos / Diabetes Mellitus Tipo 1 / Memória Imunológica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2013 Tipo de documento: Article